Citigroup upgraded shares of Hikma Pharmaceuticals (LON:HIK) to a buy rating in a report released on Thursday, March 15th. Citigroup currently has GBX 1,250 ($17.55) target price on the stock.
HIK has been the subject of several other reports. JPMorgan Chase boosted their target price on Hikma Pharmaceuticals from GBX 1,000 ($14.04) to GBX 1,050 ($14.74) and gave the stock a neutral rating in a research note on Thursday, March 15th. Numis Securities started coverage on Hikma Pharmaceuticals in a report on Wednesday, March 14th. They set a buy rating and a GBX 1,300 ($18.25) price target for the company. Jefferies Group raised Hikma Pharmaceuticals to a hold rating and boosted their target price for the company from GBX 895 ($12.56) to GBX 997 ($13.99) in a report on Thursday, March 15th. Peel Hunt reaffirmed a hold rating and set a GBX 1,180 ($16.56) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, March 14th. Finally, Morgan Stanley reaffirmed an equal weight rating and set a GBX 1,100 ($15.44) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of GBX 1,083.20 ($15.20).
LON:HIK opened at GBX 1,204 ($16.90) on Thursday. Hikma Pharmaceuticals has a 52 week low of GBX 814.20 ($11.43) and a 52 week high of GBX 2,346 ($32.93).
The company also recently announced a dividend, which will be paid on Thursday, May 24th. Investors of record on Thursday, April 5th will be given a $0.23 dividend. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.22. This represents a dividend yield of 1.47%. The ex-dividend date is Thursday, April 5th.
ILLEGAL ACTIVITY WARNING: “Hikma Pharmaceuticals (HIK) Stock Rating Upgraded by Citigroup” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/hikma-pharmaceuticals-hik-upgraded-to-buy-at-citigroup.html.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.